Orthofix International offloads its vascular compression products business to Covidien, saying it will net about $19 million from the deal, and boosts its full-year earnings guidance.
Orthofix International NV (NSDQ:OFIX) sold its vascular compression products business to Covidien (NYSE:COV) in a deal it said should yield about $19 million Orthofix will use to pay down its debt.
The Dutch firm, which maintains its U.S. headquarters in Boston, said the deal includes its AV-Impulse mechanical compression technology and is aimed at focusing on "strategic market segments that represent long term growth potential," CEO Alan Milinazzo said in prepared remarks.
Covidien champions positive results for the Barrett's esophagus ablation device it acquired along...
Illinois healthcare giant Abbott lands European regulatory approval for the Xience Xpedition 48,...
ALung Technologies says it's going for a Chinese regulatory nod for its Hemolung respiratory assist...
An attorney for a plaintiff suing robot-assisted surgical systems maker Intuitive Surgical says the...
The American Stroke Assn. and partners release the Spot a Stroke F.A.S.T. smartphone app to help...